Mesenchymal stem cells as vectors for lung cancer therapy

Respiration

Volumn 85, Issue 6, 2013, Pages 443-451

  Kolluri, Krishna K ^a   Laurent, Geoff J ^b   Janes, Sam M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apoptosis; Delivery vectors; Homing; Lung cancer; Mesenchymal stem cells; TRAIL

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER GROWTH; CELL HOMING; GENE DELIVERY SYSTEM; GENE VECTOR; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; MEDIATOR; MESENCHYMAL STEM CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THERAPY EFFECT;

EID: 84878504643     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000351284     Document Type: Article

References (95)

1. Jemal A, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Ferlay J, Shin HR, Bray F, et al. Globocan 2008: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, International Agency for Research on Cancer, 2010. http://globocan.iarc.fr.
3. Jemal A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 259-259.
4. Crino L, Foglietta J, Hamzaj A. Development of new first-line therapeutic options for nonsmall-cell lung cancer. Lung Cancer 2006; 54:S19-S24.
5. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
6. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004; 32: 414-425.
7. Weiss DJ. Stem cells and cell therapies for cystic fibrosis and other lung diseases. Pulm Pharmacol Ther 2008; 21: 588-594.
8. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patients bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35.
9. Bonnet D. Biology of human bone marrow stem cells. Clin Exp Med 2003; 3: 140-149.
10. Loebinger MR, et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69: 4134-4142.
11. Loebinger MR, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 2009; 69: 8862-8867.
12. Khakoo AY, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203: 1235-1247.
13. Nakamizo A, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
14. Lopez Ponte A, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-1745.
15. Ringe J, et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2 and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007; 101: 135-146.
16. Honczarenko M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-1041.
17. Sordi V, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427.
18. Von Luttichau I, et al. Human adult CD34(-) progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 2005; 14: 329-336.
19. Phillips RJ, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-446.
20. Xu J, et al. Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol 2007; 37: 291-299.
21. Dwyer RM, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007; 13: 5020-5027.
22. Orimo A, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
23. Cheng Z, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16: 571-579.
24. Ip JE, et al. Mesenchymal stem cells use integrin beta 1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007; 18: 2873-2882.
25. Rombouts WJC, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17: 160-170.
26. Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749.
27. Ozaki Y, et al. Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16: 119-129.
28. Chen X, et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008; 16: 749-756.
29. Xin H, et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007; 25: 1618-1626.
30. Kidd S, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010; 12: 615-625.
31. Studeny M, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferonbeta delivery into tumors. Cancer Res 2002; 62: 3603-3608.
32. Studeny M, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004; 96: 1593-1603.
33. Ren C, Kumar S, Chanda D, et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008; 15: 1446-1453.
34. Gao P, et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010; 290: 157-166.
35. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-333.
36. Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
37. Hakkarainen T, et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007; 18: 627-641.
38. Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007; 105: 157-167.
39. Komarova S, et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-766.
40. Mader EK, Butler G, Dowdy SC, et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med 2013; 11: 20.
41. Uchibori R, et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009; 11: 373-381.
42. Kucerova L, Matuskova M, Pastorakova A, et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008; 10: 1071-1082.
43. Kucerova L, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-6313.
44. Choi SA, et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer 2011; 48: 129-137.
45. Yeo RWY, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev 2013; 65: 336-341.
46. Alvarez-Erviti L, et al. Delivery of siRNA to the brain by systemic injection of targeted exosomes. Hum Gene Ther 2011; 22:A42-A42.
47. Li L, et al. Silica nanorattle-doxorubicin-Anchored mesenchymal stem cells for tumortropic therapy. Acs Nano 2011; 5: 7462-7470.
48. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
49. Mahalingam D, et al. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-288.
50. Riccioni R, Pasquini L, Mariani G, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612-624.
51. Song JH, et al. Lipid rafts and nonrafts mediate tumor necrosis factor-related apoptosisinducing ligand-induced apoptotic and nonapoptotic signals in non-small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-6955.
52. Wagner KW, Punnoose EA, Januario T et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-1077.
53. Clancy L, et al. Preligand assembly domainmediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-18104.
54. Xiang H, et al. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004; 32: 1230-1238.
55. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009; 27: 2320-2330.
56. Mohr A, Albarenque SM, Deedigan L, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010; 28: 2109-2120.
57. Li HL, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
58. Shamimi-Noori S, et al. Cisplatin enhances the antitumor effect of tumor necrosis factorrelated apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 2008; 15: 356-370.
59. Sonnemann J, et al. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 2005; 23: 99-109.
60. Su L, Liu G, Hao X, et al. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer 2011; 47: 2471-2478.
61. Ding W, et al. Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett 2010; 293: 158-166.
62. Vaculova A, Kaminskyy V, Jalalvand E, et al. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer 2010; 9: 87.
63. Luster TA, Carrell JA, McCormick K, et al. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther 2009; 8: 292-302.
64. Ciavarella S, et al. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol 2012; 157: 586-598.
65. Kim DR, et al. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther 2011; 18: 467-477.
66. Kataoka T, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/ granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161: 3936-3942.
67. Okano H, et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 2003; 83: 1033-1043.
68. Gill C, Dowling C, O'Neill AJ, et al. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 2009; 8: 39.
69. Albarenque SM, et al. RNAi-mediated inhibition of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL inhibits metastatic growth of pancreatic carcinoma cells. J Comp Pathol 2010; 143: 330-330.
70. Stadel D, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL Receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP Inhibitors. Clin Cancer Res 2010; 16: 5734-5749.
71. Wu X-X, et al. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 2007; 98: 1969-1976.
72. Glennie S, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
73. Corcione A, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
74. Ramasamy R, Fazekasova H, Lam EWF, et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76.
75. LeBlanc K, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
76. Assmus B, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222-1232.
77. Schaechinger V, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221.
78. Hare JM, Chaparro SV. Cardiac regeneration and stem cell therapy. Curr Opin Organ Transplant 2008; 13: 536-542.
79. Lunde K, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-1209.
80. Ortiz LA, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407-8411.
81. Islam MN, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18: 759-765.
82. Nakamura K, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11: 1155-1164.
83. Sun B, Roh KH, Park JR, et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy 2009; 11: 289-298.
84. Qiao L, Zhao TJ, Wang FZ, et al. NF-kappaB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells. Acta Pharmacol Sin 2008; 29: 333-340.
85. Djouad F, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-3844.
86. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
87. Sasser AK, et al. Interleukin-6 is a potent growth factor for ER-Alpha-positive human breast cancer. FASEB J 2007; 21: 3763-3770.
88. Sasser AK, et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett 2007; 254: 255-264.
89. Sanchez CG, et al. Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis 2011; 32: 964-972.
90. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-3039, 4969.
91. Wang Y, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7: 509-519.
92. Aguilar S, et al. Murine but not human mesenchymal stem cells generate osteosarcomalike lesions in the lung. Stem Cells 2007; 25: 1586-1594.
93. Houghton J, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306: 1568-1571.
94. Bernardo ME, et al. Human bone marrowderived mesenchymal stem cells do not undergo transformation after long-Term in vitro culture and do not exhibit telomere maintenance mechanisms. Blood 2007; 110: 367A.
95. clinicaltrials.gov. Clinical trials related to search term Mesenchymal stem cells. 2013. http://clinicaltrials.gov/ct2/results?term= mesenchymal+stem+cells.